Navigation Links
Infection in pregnancy can lead to congenital eye defects

In a study done by scientists of England, congenital eye defects in babies like small eyes or having no eyes //at all may be traced back to the maternal infections.

Infections like Rubella in pregnancy are known to cause such birth defects. Now studies have shown that infections such as from Parvovirus and Coxsackie virus may also be responsible for birth defects in newborns.

The researchers have taken the birth details from the England registry, and matched them with the weekly infections data from the Public Health Laboratory Service and Royal College of General Practitioners Weekly Returns Service. The researchers then have matched the infections of the pregnant mothers with the time of pregnancy when the ocular development happens for the fetus to find out the kind of health the pregnant lady was in when her unborn baby’s eyes were developed.

The study results confirmed the negative effect of Parvovirus B19 and influenza with development of eyes in the fetus, while Coxsackie virus had showed a positive effect on development of eyes in unborn babies.

The researchers feel that this further strengthens the fact that viral infections of the pregnant mother do affect the babies and more research is required to decide on the course of treatment
'"/>




Page: 1

Related medicine news :

1. Patients With Filariasis More Prone To HIV Infection
2. Infection linked with heart attack
3. Link Between Infection And Heart Disease
4. Supplements for Ear Infections
5. Once-Daily Cipro(R) XR for Treating Complicated Urinary Tract Infections
6. Oral Medication Effective In Combating Eye Infection
7. The Effectiveness Of Antibacterial Products In Reducing Infection
8. Link Between Ear Infections And Asthma
9. Reducing The Rate Of Infections
10. Good News For Individuals Suffering From Frequent Throat Infections
11. Reducing The Rate Of Hospital Acquired Infections
Post Your Comments:
Breaking Medicine Technology:ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 2ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 3ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Dynatronics Receives 180-Day NASDAQ Extension 2Botsford Hospital Cancer Center Earns Silver LEED Certification from the U S Green Building Council 58997 1Botsford Hospital Cancer Center Earns Silver LEED Certification from the U S Green Building Council 58997 2Botsford Hospital Cancer Center Earns Silver LEED Certification from the U S Green Building Council 58997 3Gen Probe to Acquire Prodesse Leader in Molecular Testing for Respiratory Infectious Diseases for 2460 Million in Cash Plus Potential Milestone Pay 14377 1Gen Probe to Acquire Prodesse Leader in Molecular Testing for Respiratory Infectious Diseases for 2460 Million in Cash Plus Potential Milestone Pay 14377 2Gen Probe to Acquire Prodesse Leader in Molecular Testing for Respiratory Infectious Diseases for 2460 Million in Cash Plus Potential Milestone Pay 14377 3Gen Probe to Acquire Prodesse Leader in Molecular Testing for Respiratory Infectious Diseases for 2460 Million in Cash Plus Potential Milestone Pay 14377 4Gen Probe to Acquire Prodesse Leader in Molecular Testing for Respiratory Infectious Diseases for 2460 Million in Cash Plus Potential Milestone Pay 14377 5Medco Announces Date for Third Quarter 2009 Financial Results 3B Company to Provide 2010 Earnings Guidance 5273 1Medco Announces Date for Third Quarter 2009 Financial Results 3B Company to Provide 2010 Earnings Guidance 5273 2